Liwen Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Liwen Li has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
Shuang Xia
Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) Southern Medical University Guangzhou China
8 shared publications- Anping Cai
Department of Cardiology, Hypertension Research Laboratory, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
7 shared publications Zhiping Gao
Department of Concord Medical Center, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
7 shared publicationsAnping Cai
Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences , No. 106, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080
6 shared publicationsXiaoju Xiao
Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China
6 shared publicationsYingling Zhou
Department of Cardiology, Hypertension Research Laboratory, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University , No. 106, Zhongshan 2nd Road, Yuexiu District, Guangzhou 510080 , China
6 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Clinical Hypertension
- Vol. 32 (1) , e23
Associations between hypertension care cascade, cognitive function, and cardiovascular disease in middle-aged and older adults: the exacerbated role of social isolation
Xiong C, et al. Clin Hypertens. 2026 ;32(1):e23. https://doi.org/10.5646/ch.2026.32.e23
- 1 January 2026
- Published by XMLink in Clinical Hypertension
- Vol. 32 (1) , e23
Open AccessAssociations between hypertension care cascade, cognitive function, and cardiovascular disease in middle-aged and older adults: the exacerbated role of social isolation
Xiong C, et al. Clin Hypertens. 2026 ;32(1):e23. https://doi.org/10.5646/ch.2026.32.e23
- Open Access
- 20 April 2025
- Published by Wiley in Journal of Arrhythmia
- Vol. 41 (2) , e70068
Prophylactic implantation of cardioverter‐defibrillator in patients with advanced light‐chain amyloidosis—A pilot study
Background: Ventricular arrhythmias (VAs) and electromechanical dissociation have been observed as the most common causes of sudden cardiac death (SCD) in patients with light chain (AL) amyloidosis. However, an implantable cardioverter‐defibrillator (ICD) has rarely been implanted in patients with advanced AL amyloidosis due to very poor prognosis. Methods: Between July 2021 and December 2022, 10 patients with advanced cardiac AL amyloidosis referred to our institute who received prophylactic ICD implantation were prospectively recruited. The primary endpoint was the prevalence of VAs and appropriate ICD therapies determined by ICD interrogation. The secondary endpoint was all‐cause mortality during the follow‐up period. Results: During a mean follow‐up of 12.1 ± 4.4 months, sustained ventricular tachycardia (VT)/ventricular fibrillation (VF) occurred in 4 of 10 (40%) patients. One patient had spontaneous termination of VT before the delivery of ICD therapy, and the remaining 3 patients had ICD therapies used, either ATP or shock. Inappropriate shock was not recorded in any patients. Patients with sustained VT/VF had wider QRS duration (143 ± 41 vs. 99 ± 10 ms, p = 0.03) and a higher incidence of bundle branch block (BBB)/interventricular conduction delay (IVCD) (75% vs. 0%, p = 0.01) compared to those without. Conclusion: VAs are commonly observed among patients with advanced AL amyloidosis, and ICD therapy can be effective in successfully treating sustained VA in these patients. On the basis of our preliminary data, prophylactic ICD implantation may be proposed to the advanced AL amyloidosis to improve the survival rate in selected patients with advanced AL amyloidosis, especially for the patients with wider QRS duration and BBB/IVCD.
- 20 April 2025
- Published by Wiley in Journal of Arrhythmia
- Vol. 41 (2) , e70068
Open AccessProphylactic implantation of cardioverter‐defibrillator in patients with advanced light‐chain amyloidosis—A pilot study
Background: Ventricular arrhythmias (VAs) and electromechanical dissociation have been observed as the most common causes of sudden cardiac death (SCD) in patients with light chain (AL) amyloidosis. However, an implantable cardioverter‐defibrillator (ICD) has rarely been implanted in patients with advanced AL amyloidosis due to very poor prognosis. Methods: Between July 2021 and December 2022, 10 patients with advanced cardiac AL amyloidosis referred to our institute who received prophylactic ICD implantation were prospectively recruited. The primary endpoint was the prevalence of VAs and appropriate ICD therapies determined by ICD interrogation. The secondary endpoint was all‐cause mortality during the follow‐up period. Results: During a mean follow‐up of 12.1 ± 4.4 months, sustained ventricular tachycardia (VT)/ventricular fibrillation (VF) occurred in 4 of 10 (40%) patients. One patient had spontaneous termination of VT before the delivery of ICD therapy, and the remaining 3 patients had ICD therapies used, either ATP or shock. Inappropriate shock was not recorded in any patients. Patients with sustained VT/VF had wider QRS duration (143 ± 41 vs. 99 ± 10 ms, p = 0.03) and a higher incidence of bundle branch block (BBB)/interventricular conduction delay (IVCD) (75% vs. 0%, p = 0.01) compared to those without. Conclusion: VAs are commonly observed among patients with advanced AL amyloidosis, and ICD therapy can be effective in successfully treating sustained VA in these patients. On the basis of our preliminary data, prophylactic ICD implantation may be proposed to the advanced AL amyloidosis to improve the survival rate in selected patients with advanced AL amyloidosis, especially for the patients with wider QRS duration and BBB/IVCD.
- Open Access
- 22 March 2024
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 11 (4) , 2023-2032
Long-Term Cost-Effectiveness of Transcatheter Mitral Valve Repair in HF Patients with Secondary Mitral Regurgitation
Aims: The long-term cost-effectiveness of MitraClip in heart failure patients with secondary mitral regurgitation is still unclear. This study aimed to evaluate the long-term cost-effectiveness of MitraClip added to guideline-directed medical therapy vs. guideline-directed medical therapy alone in heart failure patients with secondary mitral regurgitation from the perspective of the healthcare systems of mainland China, the United Kingdom, Germany, and the United States. Methods and results: A two-stage (decision + Markov) model was built. Health utilities were defined by the New York Heart Association class, heart failure re-hospitalization, and death and were calculated based on the 5 year follow-up results of the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation trial. Direct healthcare costs were derived from the nationally representative data. Future utilities and costs were discounted at country-specific rates. The primary outcome was the lifetime incremental cost-effectiveness ratio. The mean age of the base case in our model was 72.2 years. Over a lifetime horizon, treatment with MitraClip was associated with 829 fewer heart failure re-hospitalizations per 1000 treated patients. The MitraClip treatment was associated with incremental quality-adjusted life-year gains of 0.71, 0.76, 0.78, and 0.78, as well as incremental cost-effectiveness ratios of ¥468 462, £28 910, €26 045, and $71 199 per quality-adjusted life-year for a lifetime horizon in mainland China, the United Kingdom, Germany, and the United States, respectively. In probabilistic sensitivity analysis, 0.2%, 59.4%, 99.6%, and 84.7% of patients were cost-effective in mainland China, the United Kingdom, Germany, and the United States at the country-specific willingness-to-pay thresholds. Conclusions: MitraClip + guideline-directed medical therapy was cost-effective in heart failure patients with secondary mitral regurgitation in the United Kingdom, Germany, and the United States, but not in mainland China from the perspective of the national healthcare system.
- 22 March 2024
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 11 (4) , 2023-2032
Open AccessLong-Term Cost-Effectiveness of Transcatheter Mitral Valve Repair in HF Patients with Secondary Mitral Regurgitation
Aims: The long-term cost-effectiveness of MitraClip in heart failure patients with secondary mitral regurgitation is still unclear. This study aimed to evaluate the long-term cost-effectiveness of MitraClip added to guideline-directed medical therapy vs. guideline-directed medical therapy alone in heart failure patients with secondary mitral regurgitation from the perspective of the healthcare systems of mainland China, the United Kingdom, Germany, and the United States. Methods and results: A two-stage (decision + Markov) model was built. Health utilities were defined by the New York Heart Association class, heart failure re-hospitalization, and death and were calculated based on the 5 year follow-up results of the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation trial. Direct healthcare costs were derived from the nationally representative data. Future utilities and costs were discounted at country-specific rates. The primary outcome was the lifetime incremental cost-effectiveness ratio. The mean age of the base case in our model was 72.2 years. Over a lifetime horizon, treatment with MitraClip was associated with 829 fewer heart failure re-hospitalizations per 1000 treated patients. The MitraClip treatment was associated with incremental quality-adjusted life-year gains of 0.71, 0.76, 0.78, and 0.78, as well as incremental cost-effectiveness ratios of ¥468 462, £28 910, €26 045, and $71 199 per quality-adjusted life-year for a lifetime horizon in mainland China, the United Kingdom, Germany, and the United States, respectively. In probabilistic sensitivity analysis, 0.2%, 59.4%, 99.6%, and 84.7% of patients were cost-effective in mainland China, the United Kingdom, Germany, and the United States at the country-specific willingness-to-pay thresholds. Conclusions: MitraClip + guideline-directed medical therapy was cost-effective in heart failure patients with secondary mitral regurgitation in the United Kingdom, Germany, and the United States, but not in mainland China from the perspective of the national healthcare system.
- Open Access
- 4 March 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (3) , e241420
Perceived Economic Burden, Mortality, and Health Status in Patients With Heart Failure
Importance: In the face of an emerging heart failure (HF) epidemic, describing the association between perceived economic burden (PEB) and health care outcomes is an important step toward more equitable and achievable care.Objectives: To examine the association between PEB and risk of 1-year clinical outcomes and HF–specific health status in patients with acute decompensated HF.Design, Setting, and Participants: This prospective, multicenter, hospital-based cohort study prospectively enrolled adult patients hospitalized for acute decompensated HF at 52 hospitals in China from August 2016 to May 2018, with 1-year follow-up. Data were analyzed on June 17, 2022.Exposure: Perceived economic burden, categorized as severe (cannot undertake expenses), moderate (can almost undertake expenses), or little (can easily undertake expenses).Main Outcomes and Measures: The clinical outcomes of the study were 1-year all-cause death and rehospitalization for HF. Heart failure–specific health status was assessed by the 12-Item Kansas City Cardiomyopathy Questionnaire (KCCQ-12).Results: Among 3386 patients, median age was 67 years (IQR, 58-75 years) and 2116 (62.5%) were men. Of these patients, 404 (11.9%) had severe PEB; 2021 (59.7%), moderate PEB; and 961 (28.4%), little PEB. Compared with patients with little PEB, those with severe PEB had increased risk of 1-year mortality (hazard ratio [HR], 1.61; 95% CI, 1.21-2.13; P < .001) but not 1-year HF rehospitalization (HR, 1.21; 95% CI, 0.98-1.49; P = .07). The mean (SD) adjusted KCCQ-12 score was lowest in patients with severe PEB and highest in patients with little PEB at baseline (40.0 [1.7] and 50.2 [1.0] points, respectively; P < .001) and at each visit (eg, 12 months: 61.5 [1.6] and 75.5 [0.9] points respectively; P < .001). Patients reporting severe PEB had a clinically significant lower 1-year KCCQ-12 score compared with those reporting little PEB (mean difference, −11.3 points; 95% CI, −14.9 to −7.6 points; P < .001).Conclusions and Relevance: In this cohort study of patients with acute decompensated HF, greater PEB was associated with higher risk of mortality and poorer health status but not with risk of HF rehospitalization. The findings suggest that PEB may serve as a convenient tool for risk estimation and as a potential target for quality-improvement interventions for patients with HF.
- 4 March 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (3) , e241420
Open AccessPerceived Economic Burden, Mortality, and Health Status in Patients With Heart Failure
Importance: In the face of an emerging heart failure (HF) epidemic, describing the association between perceived economic burden (PEB) and health care outcomes is an important step toward more equitable and achievable care.Objectives: To examine the association between PEB and risk of 1-year clinical outcomes and HF–specific health status in patients with acute decompensated HF.Design, Setting, and Participants: This prospective, multicenter, hospital-based cohort study prospectively enrolled adult patients hospitalized for acute decompensated HF at 52 hospitals in China from August 2016 to May 2018, with 1-year follow-up. Data were analyzed on June 17, 2022.Exposure: Perceived economic burden, categorized as severe (cannot undertake expenses), moderate (can almost undertake expenses), or little (can easily undertake expenses).Main Outcomes and Measures: The clinical outcomes of the study were 1-year all-cause death and rehospitalization for HF. Heart failure–specific health status was assessed by the 12-Item Kansas City Cardiomyopathy Questionnaire (KCCQ-12).Results: Among 3386 patients, median age was 67 years (IQR, 58-75 years) and 2116 (62.5%) were men. Of these patients, 404 (11.9%) had severe PEB; 2021 (59.7%), moderate PEB; and 961 (28.4%), little PEB. Compared with patients with little PEB, those with severe PEB had increased risk of 1-year mortality (hazard ratio [HR], 1.61; 95% CI, 1.21-2.13; P < .001) but not 1-year HF rehospitalization (HR, 1.21; 95% CI, 0.98-1.49; P = .07). The mean (SD) adjusted KCCQ-12 score was lowest in patients with severe PEB and highest in patients with little PEB at baseline (40.0 [1.7] and 50.2 [1.0] points, respectively; P < .001) and at each visit (eg, 12 months: 61.5 [1.6] and 75.5 [0.9] points respectively; P < .001). Patients reporting severe PEB had a clinically significant lower 1-year KCCQ-12 score compared with those reporting little PEB (mean difference, −11.3 points; 95% CI, −14.9 to −7.6 points; P < .001).Conclusions and Relevance: In this cohort study of patients with acute decompensated HF, greater PEB was associated with higher risk of mortality and poorer health status but not with risk of HF rehospitalization. The findings suggest that PEB may serve as a convenient tool for risk estimation and as a potential target for quality-improvement interventions for patients with HF.
- Top Cited PapersOpen Access
- 28 January 2024
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 23 (1) , 1-12
The association between TyG and all-cause/non-cardiovascular mortality in general patients with type 2 diabetes mellitus is modified by age: results from the cohort study of NHANES 1999–2018
Background: The prognostic value of triglyceride-glucose (TyG) index in general type 2 diabetes mellitus (T2DM) patients is still unclear. Therefore, we aimed to determine the associations between TyG and all-cause/cause-specific death in a T2DM cohort and explore whether such associations would be modified by age. Methods: A total of 3,376 patients with T2DM from the National Health and Nutrition Examination Survey (NHANES) 1999–2018 were selected and divided into the younger group (< 65 yrs) and the older group (≥ 65 yrs). Baseline TyG was calculated and cause-specific mortality status [cardiovascular (CV), cancer, and non-CV] was determined by the NHANES Public-Use Linked Mortality Files through 31 December 2019. Multivariate Cox and restricted cubic spline (RCS) regression models were used to evaluate the association between TyG and all-cause/cause-specific mortality. Interaction between TyG and age to mortality was also evaluated. Sensitivity analyses were performed in patients without cardiovascular disease, chronic kidney disease, or insulin treatment. Results: During a median follow-up of 107 months, 805 all-cause deaths occurred, of which 250 and 144 were attributed to CV and cancer deaths. There was a significant age interaction to the association between TyG and all-cause/non-CV mortality. After fully adjusting for potential confounding factors, higher TyG was associated with an increased risk of all-cause [TyG per unit increase Hazard Ratio (HR) 1.33, 95% Confidence Interval (CI) 1.06–1.66, p = 0.014] and non-CV mortality (TyG per unit increase HR 1.54, 95% CI 1.18–2.01, p = 0.002) only in the younger group, but not in the older group. There was no significant association between TyG and CV/cancer death in the total cohort and two age subgroups. Similar results were found in RCS and sensitivity analyses. Conclusion: In a national sample of patients with T2DM in the United States, we found that the association between TyG and all-cause/non-CV death was modified by age. Higher TyG was only associated with an increased risk of all-cause/non-CV only in T2DM patients younger than 65 years old, but not in older patients.
- 28 January 2024
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 23 (1) , 1-12
Top Cited PapersOpen AccessThe association between TyG and all-cause/non-cardiovascular mortality in general patients with type 2 diabetes mellitus is modified by age: results from the cohort study of NHANES 1999–2018
Background: The prognostic value of triglyceride-glucose (TyG) index in general type 2 diabetes mellitus (T2DM) patients is still unclear. Therefore, we aimed to determine the associations between TyG and all-cause/cause-specific death in a T2DM cohort and explore whether such associations would be modified by age. Methods: A total of 3,376 patients with T2DM from the National Health and Nutrition Examination Survey (NHANES) 1999–2018 were selected and divided into the younger group (< 65 yrs) and the older group (≥ 65 yrs). Baseline TyG was calculated and cause-specific mortality status [cardiovascular (CV), cancer, and non-CV] was determined by the NHANES Public-Use Linked Mortality Files through 31 December 2019. Multivariate Cox and restricted cubic spline (RCS) regression models were used to evaluate the association between TyG and all-cause/cause-specific mortality. Interaction between TyG and age to mortality was also evaluated. Sensitivity analyses were performed in patients without cardiovascular disease, chronic kidney disease, or insulin treatment. Results: During a median follow-up of 107 months, 805 all-cause deaths occurred, of which 250 and 144 were attributed to CV and cancer deaths. There was a significant age interaction to the association between TyG and all-cause/non-CV mortality. After fully adjusting for potential confounding factors, higher TyG was associated with an increased risk of all-cause [TyG per unit increase Hazard Ratio (HR) 1.33, 95% Confidence Interval (CI) 1.06–1.66, p = 0.014] and non-CV mortality (TyG per unit increase HR 1.54, 95% CI 1.18–2.01, p = 0.002) only in the younger group, but not in the older group. There was no significant association between TyG and CV/cancer death in the total cohort and two age subgroups. Similar results were found in RCS and sensitivity analyses. Conclusion: In a national sample of patients with T2DM in the United States, we found that the association between TyG and all-cause/non-CV death was modified by age. Higher TyG was only associated with an increased risk of all-cause/non-CV only in T2DM patients younger than 65 years old, but not in older patients.
- 4 October 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (44) , 4715-4718
Sex-specific characteristics and outcomes in hospitalized heart failure with preserved ejection fraction: the China Cardiovascular Association Database-Heart Failure Center Registry
Sex-differences in characteristics and outcome in heart failure with preserved ejection fraction (HFpEF) have been well documented.1,2 However, whether these differences vary by left ventricular ejection fraction (LVEF) are unclear. A recent study showed substantial differences in morphological and hemodynamic characteristics in HFpEF patients with high-normal (>60%) vs. low-normal (50%–60%) LVEF, which might partly explain their heterogeneous responses to pharmacotherapy.3 Post-hoc analyses of clinical trials suggest that the benefits of neurohormonal modulators extended to a higher range of LVEF in women than in men.4,5 It is therefore important to compare clinical characteristics and outcomes between male and female HFpEF patients by LVEF. Additionally, recent epidemiologic studies reported a new phenotype characterized by supranormal LVEF (LVsnEF);6,7 whether there are sex differences in LVsnEF deserves further investigation. The China Cardiovascular Association (CCA) Database-Heart Failure (HF) Center Registry is a nationwide multicentre study, which was approved by the Central Ethics Committee of Beijing Hospital (2018BJYYEC-059-02).8 All secondary and tertiary hospitals from mainland China are welcome to participate in the registry, and no additional specific selection criteria are required. Between January 2017 and December 2021, 575 CCA Database-HF Center-certified secondary and tertiary hospitals across the 31 provinces of mainland China participated in the registry. Hospitalized patients with a principal discharge diagnosis of HF were eligible for the registry, and those who died during index hospitalization were excluded. Diagnostic criteria of HF are based on the guidelines,9,10 including presence of clinical symptoms/signs of HF, cardiac structural and/or functional abnormality on echocardiogram, and elevated serum natriuretic peptide level. If LVEF was ≥50% as measured by echocardiography at index hospitalization, HF was defined as HFpEF.9,10 Among the overall HFpEF patients recruited (n = 125 208), after excluding those who were lost to follow-up (n = 8321), had n = 65 151), or lacked sex data (n = 25), 51 711 hospitalized HFpEF patients were included. Data from electronic and/or physical health records were collected and entered into an online central database by trained staff. Study variables collected included demographics, anthropometrics, education, vital signs at admission, HF characteristics [precipitating factors for index HF admission, hospitalization for HF (HHF) in the previous 12 months, clinical symptoms/signs, New York Heart Association (NYHA) class], laboratory and echocardiography data, comorbidities [smoking status, alcohol consumption, hypertension, diabetes mellitus, dyslipidaemia, obesity, chronic kidney disease (CKD), atrial fibrillation (AF), coronary heart disease (CHD), prior myocardial infarction, prior stroke/transient ischaemic attack, peripheral arterial disease, chronic obstructive pulmonary disease (COPD), anaemia, thyroid dysfunction, obstructive sleep apnoea, anxiety/depression, and cancer], prior intervention and device therapy, and medications prescribed at discharge. After discharge, patients were followed by trained physicians during an outpatient visit or via a telephone interview during the first week (±1 week), the first month (±14 days), the third month (±30 days), and the first year (±90 days). The primary outcome was a composite of HHF or cardiovascular death. Follow-up duration was calculated from the date of discharge until the occurrence of the first event (HHF or cardiovascular death) or at the end of 1-year follow-up if no event occurred. All-cause death and all-cause hospitalization were evaluated as secondary outcomes. All events were reported by the participants or their immediate relatives without adjudication.
- 4 October 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (44) , 4715-4718
Sex-specific characteristics and outcomes in hospitalized heart failure with preserved ejection fraction: the China Cardiovascular Association Database-Heart Failure Center Registry
Sex-differences in characteristics and outcome in heart failure with preserved ejection fraction (HFpEF) have been well documented.1,2 However, whether these differences vary by left ventricular ejection fraction (LVEF) are unclear. A recent study showed substantial differences in morphological and hemodynamic characteristics in HFpEF patients with high-normal (>60%) vs. low-normal (50%–60%) LVEF, which might partly explain their heterogeneous responses to pharmacotherapy.3 Post-hoc analyses of clinical trials suggest that the benefits of neurohormonal modulators extended to a higher range of LVEF in women than in men.4,5 It is therefore important to compare clinical characteristics and outcomes between male and female HFpEF patients by LVEF. Additionally, recent epidemiologic studies reported a new phenotype characterized by supranormal LVEF (LVsnEF);6,7 whether there are sex differences in LVsnEF deserves further investigation. The China Cardiovascular Association (CCA) Database-Heart Failure (HF) Center Registry is a nationwide multicentre study, which was approved by the Central Ethics Committee of Beijing Hospital (2018BJYYEC-059-02).8 All secondary and tertiary hospitals from mainland China are welcome to participate in the registry, and no additional specific selection criteria are required. Between January 2017 and December 2021, 575 CCA Database-HF Center-certified secondary and tertiary hospitals across the 31 provinces of mainland China participated in the registry. Hospitalized patients with a principal discharge diagnosis of HF were eligible for the registry, and those who died during index hospitalization were excluded. Diagnostic criteria of HF are based on the guidelines,9,10 including presence of clinical symptoms/signs of HF, cardiac structural and/or functional abnormality on echocardiogram, and elevated serum natriuretic peptide level. If LVEF was ≥50% as measured by echocardiography at index hospitalization, HF was defined as HFpEF.9,10 Among the overall HFpEF patients recruited (n = 125 208), after excluding those who were lost to follow-up (n = 8321), had n = 65 151), or lacked sex data (n = 25), 51 711 hospitalized HFpEF patients were included. Data from electronic and/or physical health records were collected and entered into an online central database by trained staff. Study variables collected included demographics, anthropometrics, education, vital signs at admission, HF characteristics [precipitating factors for index HF admission, hospitalization for HF (HHF) in the previous 12 months, clinical symptoms/signs, New York Heart Association (NYHA) class], laboratory and echocardiography data, comorbidities [smoking status, alcohol consumption, hypertension, diabetes mellitus, dyslipidaemia, obesity, chronic kidney disease (CKD), atrial fibrillation (AF), coronary heart disease (CHD), prior myocardial infarction, prior stroke/transient ischaemic attack, peripheral arterial disease, chronic obstructive pulmonary disease (COPD), anaemia, thyroid dysfunction, obstructive sleep apnoea, anxiety/depression, and cancer], prior intervention and device therapy, and medications prescribed at discharge. After discharge, patients were followed by trained physicians during an outpatient visit or via a telephone interview during the first week (±1 week), the first month (±14 days), the third month (±30 days), and the first year (±90 days). The primary outcome was a composite of HHF or cardiovascular death. Follow-up duration was calculated from the date of discharge until the occurrence of the first event (HHF or cardiovascular death) or at the end of 1-year follow-up if no event occurred. All-cause death and all-cause hospitalization were evaluated as secondary outcomes. All events were reported by the participants or their immediate relatives without adjudication.
- Open Access
- 1 October 2023
- Published by Wolters Kluwer Health in Cardiology Plus
- Vol. 8 (4) , 263-268
Relationship between dapagliflozin and urinary albumin-to-creatinine ratio in patients with diabetes mellitus and cardiovascular disease: an observational study
Background and purpose: The potential impact of dapagliflozin on the urinary albumin-to-creatinine ratio (UACR) in patients with type 2 diabetes and cardiovascular disease remained inconclusive. We aimed to investigate the potential impact of dapagliflozin on the UACR in patients with diabetes mellitus complicated with cardiovascular disease. Methods: This is a single-center prospective observation study. Diabetic patients with cardiovascular disease were recruited at authors’ center (both outpatients and inpatients) during a period from June 2019 to November 2020. The study subjects were grouped into a dapagliflozin group (receiving dapagliflozin for at least 6 consecutive months) and a non-sodium-glucose cotransporter 2 inhibitors (SGLT2i) group (not receiving dapagliflozin or any other SGLT2i). LgUACR change at 6 months from the baseline were compared between the two groups. Results: A total of 57 patients were enrolled during a period from June 2019 to November 2020: 35 in the dapagliflozin group versus 22 in the non-SGLT2i group. LgUACR change from the baseline was −0.07 in the dapagliflozin group, and 0.17 in the non-SGLT2i group (P = 0.021). Dapagliflozin was associated with a decrease in UACR in the univariate regression analysis but not in the analysis of covariance. Conclusions: Dapagliflozin may be associated with a decrease in the UACR in patients with diabetes mellitus and cardiovascular disease. In view of the limited sample size, further investigation is needed to verify these findings.
- 1 October 2023
- Published by Wolters Kluwer Health in Cardiology Plus
- Vol. 8 (4) , 263-268
Open AccessRelationship between dapagliflozin and urinary albumin-to-creatinine ratio in patients with diabetes mellitus and cardiovascular disease: an observational study
Background and purpose: The potential impact of dapagliflozin on the urinary albumin-to-creatinine ratio (UACR) in patients with type 2 diabetes and cardiovascular disease remained inconclusive. We aimed to investigate the potential impact of dapagliflozin on the UACR in patients with diabetes mellitus complicated with cardiovascular disease. Methods: This is a single-center prospective observation study. Diabetic patients with cardiovascular disease were recruited at authors’ center (both outpatients and inpatients) during a period from June 2019 to November 2020. The study subjects were grouped into a dapagliflozin group (receiving dapagliflozin for at least 6 consecutive months) and a non-sodium-glucose cotransporter 2 inhibitors (SGLT2i) group (not receiving dapagliflozin or any other SGLT2i). LgUACR change at 6 months from the baseline were compared between the two groups. Results: A total of 57 patients were enrolled during a period from June 2019 to November 2020: 35 in the dapagliflozin group versus 22 in the non-SGLT2i group. LgUACR change from the baseline was −0.07 in the dapagliflozin group, and 0.17 in the non-SGLT2i group (P = 0.021). Dapagliflozin was associated with a decrease in UACR in the univariate regression analysis but not in the analysis of covariance. Conclusions: Dapagliflozin may be associated with a decrease in the UACR in patients with diabetes mellitus and cardiovascular disease. In view of the limited sample size, further investigation is needed to verify these findings.
- Open Access
- 31 August 2023
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 10 (5) , 2797-2806
Lagging Behind the Western Countries: The Knowledge Gaps of Gender Differences in Heart Failure in Asia
Gender differences in heart failure (HF), ranging from epidemiological and pathophysiological factors to therapeutic response and prognosis, have been well documented in Western countries, especially in Europe and North America. The above gender differences in HF found in Westerners are rarely investigated in Asians. In this review, we explore the worrying knowledge gap on the gender differences in HF that existed in Asia in contrast with Western populations based on the following four aspects: epidemiology, risk factors, therapy, and prognosis. Finally, we conclude that investigations of gender differences in HF in Asia lag behind those in Europe and North America. Future work is required to establish and better use the high-level, population-based cohorts and develop our own high-quality, convincing clinical trials to deliver robust gender-specific conclusions in Asia.
- 31 August 2023
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 10 (5) , 2797-2806
Open AccessLagging Behind the Western Countries: The Knowledge Gaps of Gender Differences in Heart Failure in Asia
Gender differences in heart failure (HF), ranging from epidemiological and pathophysiological factors to therapeutic response and prognosis, have been well documented in Western countries, especially in Europe and North America. The above gender differences in HF found in Westerners are rarely investigated in Asians. In this review, we explore the worrying knowledge gap on the gender differences in HF that existed in Asia in contrast with Western populations based on the following four aspects: epidemiology, risk factors, therapy, and prognosis. Finally, we conclude that investigations of gender differences in HF in Asia lag behind those in Europe and North America. Future work is required to establish and better use the high-level, population-based cohorts and develop our own high-quality, convincing clinical trials to deliver robust gender-specific conclusions in Asia.
- Open Access
- 1 July 2023
- Published by Wolters Kluwer Health in Cardiology Plus
- Vol. 8 (3) , 206-210
Negative methylene diphosphonate scintigraphy in biopsy-confirmed hereditary transthyretin Ala117Ser cardiac amyloidosis: a case report
99mTc-pyrophosphate (99mTc-PYP) scintigraphy is highly sensitive and specific for the diagnosis of transthyretin cardiac amyloidosis (ATTR-CA). Commonly used alternative tracers included 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) and 99mTc-hydroxymethylene diphosphonate (99mTc-HMDP). A 61-year-old Chinese man presented with signs indicative of left ventricular hypertrophy. Genetic testing revealed heterozygous transthyretin Ala117Ser mutation. Scintigraphy using 99mTc-methylene diphosphonate failed to show myocardial uptake. Five months later, the patient underwent permanent pacemaker implantation. Tafamidis was used irregularly, and the patient died 2 years later. 99mTc-methylene diphosphonate may not be appropriate for diagnostic use in ATTR-CA patient with transthyretin Ala117Ser mutation.
- 1 July 2023
- Published by Wolters Kluwer Health in Cardiology Plus
- Vol. 8 (3) , 206-210
Open AccessNegative methylene diphosphonate scintigraphy in biopsy-confirmed hereditary transthyretin Ala117Ser cardiac amyloidosis: a case report
99mTc-pyrophosphate (99mTc-PYP) scintigraphy is highly sensitive and specific for the diagnosis of transthyretin cardiac amyloidosis (ATTR-CA). Commonly used alternative tracers included 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) and 99mTc-hydroxymethylene diphosphonate (99mTc-HMDP). A 61-year-old Chinese man presented with signs indicative of left ventricular hypertrophy. Genetic testing revealed heterozygous transthyretin Ala117Ser mutation. Scintigraphy using 99mTc-methylene diphosphonate failed to show myocardial uptake. Five months later, the patient underwent permanent pacemaker implantation. Tafamidis was used irregularly, and the patient died 2 years later. 99mTc-methylene diphosphonate may not be appropriate for diagnostic use in ATTR-CA patient with transthyretin Ala117Ser mutation.